- Rafael S Scheffel, endocrinologist,
- Beatriz D Schaan, postgraduate student
- 1Hospital de Clínicas de Porto Alegre, Serviço de Medicina Interna, Porto Alegre, RS, Brazil
Although Karagiannis and colleagues’ study has methodological strengths worth citing, we disagree with some of the conclusions.
In the evaluation of the prespecified primary endpoint (difference in glycated haemoglobin (HbA1c); fig 2), the performance of the dipeptidyl peptidase-4 (DPP-4) inhibitors was far below that of the drugs used as active comparators …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.